ABOUT US

Our Mission

Turnstone Biologics’ mission is to deliver breakthrough viral immunotherapies to improve survival for people with cancer.

Turnstone Biologics is a privately-held immuno-oncology company with offices in New York (USA) and Ottawa (Canada). Since 2015, we have raised $50 million in venture capital financing, brought in more than $100 million in non-dilutive funding, and have received numerous biotechnology industry awards, including being named a 2017 Fierce 15 company.

 

Our scientific founders, Drs. John Bell, David Stojdl and Brian Lichty, are world leaders in the oncolytic virus and immunotherapy field. Collectively, they have published more than 200 publications in leading journals, and have spent years engineering and developing viruses to create the next generation of powerful, targeted therapies for cancer patients.

 

Our passionate team of leaders in oncology has decades of experience in biotechnology, academia and pharmaceutical drug development. With comprehensive capabilities in immuno-oncology discovery, basic research, translation, clinical development, manufacturing, and commercialization, we are committed to bringing new medicines to people with cancer to improve their lives.

 

our science

Breakthrough Viral Immunotherapies

Turnstone Biologics is developing a disruptive class of engineered viral immunotherapies, attacking cancer’s complexity with medicines designed to fight tumors at multiple points of intervention, including simultaneous generation of targeted immune responses and modulation of the tumor environment.

The Vaccinia Virus

Turnstone’s proprietary vaccinia virus platform has been engineered to stimulate the immune system, drive antigen presentation and recognition, and re-shape the tumor microenvironment. The high degree of tumor selectivity and large transgene capacity of the virus can be utilized to deliver other agents and therapeutics directly to sites of tumors throughout the body for local expression, reducing their potential for systemic toxicity.

RIVAL-01 is Turnstone’s lead candidate consisting of the vaccinia virus backbone encoding three potent immunomodulators, Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, specifically designed to work together to drive immune activity and re-program the microenvironment to be best suited for tumor eradication. When the vaccinia virus enters and replicates in cancer cells throughout the body, the transgenes are expressed. The resulting local production of these therapeutics at the site of tumors add to the inherent oncolytic and microenvironment modifying properties of the virus to form a powerful multi-modal attack on the disease.

our team

Leadership

Turnstone Biologics was founded by world-leading experts in oncolytic viruses and immunotherapies who have defined and advanced the field over the course of multiple decades. Our leadership team includes experts from academia and the life sciences industry who share the vision of bringing innovative viral immunotherapies based on our unique vaccinia virus platform to people with cancer.

close
Sammy Farah, Ph.D., M.B.A.

Sammy Farah, Ph.D., M.B.A.

President & Chief Executive Officer

Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
Mike Burgess, M.B.Ch.B., Ph.D.

Mike Burgess, M.B.Ch.B., Ph.D.

President, Research & Development

Dr. Mike Burgess brings 20 years of drug research and development experience to Turnstone Biologics. At Bristol-Myers Squibb, he led strategy and execution of translational medicine, early-stage clinical trials and clinical pharmacology across all therapeutic areas, including oncology. Prior to this at Roche, Mike held several different senior leadership positions, including acting global head of Roche Pharma Research and Early Development (pRED) and Senior Vice President and Global Head of Oncology Research and Early Development. Before joining Roche, Mike spent 7 years at Lilly working on early stage oncology trials. Mike received his medical degree (MBChB) and a Ph.D. in molecular biology from the University of Bristol, UK and spent 10 years as a practicing physician in pediatrics and pediatric oncology.

close
Jane Pritchett Henderson

Jane Pritchett Henderson

Chief Financial Officer

Jane Pritchett Henderson brings nearly 30 years of experience in health care and life sciences to her new role as Chief Financial Officer of Turnstone. Previously, she served as Chief Financial Officer and Senior Vice President of Corporate Development of Voyager Therapeutics since January 2017. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in early 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc., in late 2016. Prior to Kolltan, Ms. Henderson served in various financial and business development leadership roles at ISTA Pharmaceuticals, Axerion Pharmaceuticals and Panacos Pharmaceuticals. In her more than 19 years in healthcare investment banking, Ms. Henderson executed more than 95 mergers and acquisitions, advisory and financing deals, holding senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms. Henderson currently serves on the Board of Directors of Sesen Bio (formerly Eleven Biotherapeutics, Inc.) and Ophthotech as well as a non-profit foundation, The EQUUS Foundation.

close
José Manuel Otero, Ph.D.

José Manuel Otero, Ph.D.

Senior Vice President, Technical Operations

Dr. José Manuel (Manny) Otero has 15 years of experience in the biopharmaceutical industry, including in bioprocess development, manufacturing, and CMC of vaccines and complex biologics. He joined Turnstone Biologics from Seres Therapeutics, Inc., a leader in human microbiome therapeutics, where he was Vice President of Bioprocess Development and Manufacturing. At Seres Therapeutics, Dr. Otero oversaw the expansion of the bioprocess development and manufacturing group, and was the corporate team leader for the first synthetic microbiome therapeutic to enter Phase 1b clinical studies in the United States. Prior to that, Dr. Otero was Director of Engineering at Merck & Co.’s Vaccine Manufacturing Sciences & Commercialization division. In that role, he supported development programs for the Varivax™, Zostavax™, ProQuad™, and MMRII™ franchises. Prior to that role, he was Head of Fermentation Process Development, Vaccine Process Development within Merck Research Labs. Dr. Otero has authored more than 20 peer-reviewed publications. He earned a Ph.D. in chemical and biological engineering from Chalmers University of Technology in Gothenburg, Sweden, and an M.Eng. in biomedical engineering and a B.S. in chemical engineering from the Massachusetts Institute of Technology.

close
Kristin Gustafson

Kristin Gustafson

Senior Vice President, HR & Facilities

Kristin Gustafson brings with her more than 18 years of Human Resources experience specific to the biotech and pharmaceutical sector to Turnstone. Prior to joining Turnstone, Ms. Gustafson was with Kite Pharma, a Gilead company, where she led the global Human Resource and Facilities function during a time of explosive growth and the approval of Yescarta, the first CAR-T adult immunotherapy approved by the U.S. Food and Drug Administration (FDA). Prior to Kite, she spent four years at Intercept Pharmaceuticals and served as the company’s Senior Vice President of Global Human Resources and Facilities and also served in leadership roles at Cochlear and MGI Pharma.  Kristin attended the University of Wisconsin, Madison.

close
Steve Bernstein, M.D.

Steve Bernstein, M.D.

Senior Vice President, Clinical Research & Development

Steven Bernstein, M.D., has more than 20 years of experience as a treating physician, translational scientist and pharmaceutical executive.  Prior to joining Turnstone, Dr. Bernstein served as Chair, Immuno-Oncology Translational Research and Development, and Head, Integrated Science, at Bristol-Myers Squibb. Prior to BMS, he was as an academic physician scientist most recently at the University of Rochester’s James P. Wilmot Cancer Institute, where he was Professor of Medicine, Co-Director of the Hematological Malignancy and Lymphoma Biology Programs and Co-PI of the University of Rochester/Arizona Cancer Center NCI SPORE grant in lymphoma. Dr. Bernstein was a member of the Lymphoma Working Group of SWOG, and the Scientific Advisory Boards of both the Lymphoma Research Foundation and the Leukemia and Lymphoma Society.

close
David Stojdl, Ph.D.

David Stojdl, Ph.D.

Senior Vice President, Discovery Research

Dr. David Stojdl pioneered the exploration of host-virus interactions critical to oncolytic therapy to guide the clinical development of more effective virus platforms. At the Ottawa Regional Cancer Centre, he first identified VSV as an oncolytic virus and defined the archetypal role of interferon signaling in tumor-specific oncolytic virus targeting. Since joining the CHEO Research Institute in 2004, Dr. Stojdl has discovered and developed several novel oncolytic vector platforms, including the Maraba oncolytic virus platform. Dr. Stojdl also directs the CHEO Automated Screening Centre (CASC), leveraging state-of-the-art high-throughput robotic screening technology to uncover new insights for the clinical development of oncolytic virus biotherapies. Dr. Stojdl is a professor in the Department of Pediatrics and Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He was a scientific co-founder and consultant to Jennerex Biotherapeutics (later acquired by SillaJen Biotherapeutics). He received a Ph.D. from the University of Ottawa and an M.S. and B.S. in microbiology and immunology from the University of Western Ontario.

close
Caroline Breitbach, Ph.D.

Caroline Breitbach, Ph.D.

Vice President, Translational Development

Dr. Caroline Breitbach joined Turnstone Biologics from SillaJen Biotherapeutics (formerly Jennerex) where she was Vice President, Clinical and Translational Research. In that position, she oversaw translational and early-stage clinical development of an oncolytic immunotherapy and contributed to lead candidate development from Phase 1 through initiation of Phase 3 evaluation. Previously, she worked in Dr. John Bell’s group at the University of Ottawa, where she evaluated acute effects of oncolytic viruses on the tumor immune microenvironment. She earned a Ph.D. in biochemistry from the University of Ottawa and an Honor’s B.Sc. in microbiology and immunology from McGill University.

close
Maura Campbell, Ph.D.

Maura Campbell, Ph.D.

Vice President, Corporate Affairs

Dr. Maura Campbell has spent more than 20 years in technology transfer and the management and commercialization of intellectual property (IP). She has business management experience in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations (National Centre of Excellence [NCE]). Maura joined Turnstone Biologics from VBI Vaccines where she served as Director, Intellectual Property. She also was with the Ottawa Hospital Research Institute (OHRI) as a Senior Research Program Manager, where she oversaw the oncolytic vaccine project commercialization. Earlier in her career, Maura was the Director of Intellectual Property for PainCeptor Pharma Corporation, the Manager of Technology Transfer & Commercialization for the OHRI, and the Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems at NCE. She has served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs. Maura received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston.

close
Karen Major

Karen Major

Vice President, Regulatory

Karen Major has 18 years of Regulatory Affairs experience, specializing in the global development of biotechnological oncology products.  Prior to joining Turnstone, she was Sr. Director Regulatory Affairs at Arbutus Biopharma, focusing on chronic HBV. Prior to that, she held the same position at Tekmira Pharmaceuticals, developing siRNA-LNP products in oncology, infectious disease and metabolic indications. Karen led the Regulatory Affairs departments at YM BioSciences (acquired by Gilead in 2013) and Viventia Biotechnologies. Karen holds an honors BSc in Pharmacology and Toxicology from the University of Toronto, a post-graduate diploma in Regulatory Affairs and Quality Operations from Seneca College, and a Regulatory Affairs Certification (RAC) from RAPS.

close
Adina Pelusio

Adina Pelusio

Vice President, Clinical Operations

Adina Pelusio has more than 15 years of experience in drug development, most recently as the Vice President, Clinical Operations at SillaJen Biotherapeutics (formerly Jennerex, Inc), where she spent a decade advancing oncolytic viruses in clinical trials. In addition to overseeing the Clinical Operations department at SillaJen, she managed and pioneered the medical educator role to expand hospital personnel comfort and knowledge globally with oncolytic viruses. Prior to Jennerex, Ms. Pelusio served as a SWAT Senior Clinical Research Associate at PPD, a large, global CRO, where she was tasked with study rescue and served on a technology committee assigned with developing training for CRAs and project teams on new technologies within the field.

close
John Bell, Ph.D.

John Bell, Ph.D.

Ottawa Hospital Research Institute

Dr. John Bell began his independent research career at McGill University before moving to the University of Ottawa and becoming a professor in the Department of Medicine. He is a member of the Center for Innovative Cancer Therapeutics at The Ottawa Hospital Cancer Center and a Senior Scientist at the Ottawa Hospital Research Institute. He heads the Canadian Oncolytic Virus Consortium, a Terry Fox-funded group from across Canada that is developing virus-based cancer therapeutics, and is the Director of the Biotherapeutics Program at the Ontario Institute for Cancer Research. John is the Scientific Director of the National Centre of Excellence for the development of Biotherapeutics for Cancer Therapy and a Fellow of the Royal Society of Canada. Dr. Bell received a Ph.D. from McMaster University and then trained at the Medical Research Council in London, U.K.

close
Brian Lichty, Ph.D.

Brian Lichty, Ph.D.

McMaster University

Dr. Brian Lichty is a distinguished scientist with extensive expertise in oncolytic viruses and related immunotherapies, including seminal work with Dr. John Bell at the Ottawa Regional Cancer Centre. He is a professor in the Department of Pathology & Molecular Medicine and the McMaster Immunology Research Centre (MIRC) at McMaster University. Dr. Lichty’s expertise includes influence research in the identification of strategies to leverage oncolytic viruses to harness the patient’s immune system in a sustainable manner, including vaccine design and engineering to directly engage the adaptive immune system tumor-specific and/or to enhance combinations with other immunotherapies. He is also director of the Robert E. Fitzhenry vector lab at McMaster University where clinical-grade viral vaccines are manufactured for human clinical trials. Dr. Lichty earned a Ph.D. from the University of Toronto and a B.Sc. from the University of Guelph.

close
David Stojdl, Ph.D.

David Stojdl, Ph.D.

University of Ottawa

Dr. David Stojdl pioneered the exploration of host-virus interactions critical to oncolytic therapy to guide the clinical development of more effective virus platforms. At the Ottawa Regional Cancer Centre, he first identified VSV as an oncolytic virus and defined the archetypal role of interferon signaling in tumor-specific oncolytic virus targeting. Since joining the CHEO Research Institute in 2004, Dr. Stojdl has discovered and developed several novel oncolytic vector platforms, including the Maraba oncolytic virus platform. Dr. Stojdl also directs the CHEO Automated Screening Centre (CASC), leveraging state-of-the-art high-throughput robotic screening technology to uncover new insights for the clinical development of oncolytic virus biotherapies. Dr. Stojdl is a professor in the Department of Pediatrics and Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He was a scientific co-founder and consultant to Jennerex Biotherapeutics (later acquired by SillaJen Biotherapeutics). He received a Ph.D. from the University of Ottawa and an M.S. and B.S. in microbiology and immunology from the University of Western Ontario.

close
Brad Bolzon, Ph.D.

Brad Bolzon, Ph.D.


Brad Bolzon, Ph.D., is a Managing Director and Chairman of Versant. He combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Brad is the architect of Versant’s investment strategy. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales) and BlueRock (sale), and he continues to manage several other promising investments.

Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Under his leadership, Roche established alliances with over 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He earned Master of Science and Ph.D. degrees in Pharmacology from the University of Toronto.

close
Jerel Davis, Ph.D.

Jerel Davis, Ph.D.


Dr. Jerel Davis is a Managing Director at Versant Ventures and is based in Vancouver. Since joining Versant in 2011, he has played a critical role in launching and investing in a number of Versant’s portfolio companies including Quanticel Pharmaceuticals, Crispr Therapeutics, Blueline Bioscience, Northern Biologics and several of the Inception Sciences discovery start-ups. He has also led Versant’s execution of build-to-buy structured acquisitions with Celgene, Roche and Bayer. Over the last few years, Jerel has focused on establishing Versant’s presence in Canada, including the launch of new companies in Vancouver, Toronto and Montreal. Prior to joining Versant, Jerel was Associate Principal at McKinsey and Company where he advised pharmaceutical, biotechnology, medical device and molecular diagnostics companies. He has worked in a number of healthcare markets globally including the United States, Europe, China, Russia and India. Jerel was a post-doctoral researcher at Stanford University and worked in research at Amgen.

close
Rishi Gupta, J.D.

Rishi Gupta, J.D.


Rishi Gupta is a private equity partner at OrbiMed. Prior to that, he was a healthcare investment banker at Raymond James & Associates, served as manager of corporate development at Veritas Medicine and was a summer associate at Wachtell, Lipton, Rosen & Katz. Rishi has published scientific articles on the mechanisms of HIV entry into host cells and legal articles on intellectual property laws in the developing world. In addition to Turnstone Biologics, he serves or has served on the boards of Dimension Therapeutics, Symbiomix Therapeutics, Avitide, Verona Pharma, ChemoCentryx and Sientra. He has also been actively involved with OrbiMed’s investments in Acceleron Pharma, CoGenesys, Supernus Pharmaceuticals, Adimab, Receptos, Aragon Pharmaceuticals, Seragon Pharmaceuticals, Alector, Arsanis, Biotie, Invitae and ORIC Pharmaceuticals. Rishi earned a J.D. from the Yale Law School and an A.B. degree magna cum laude in biochemical sciences from Harvard College.

close
Sammy Farah, Ph.D., M.B.A.

Sammy Farah, Ph.D., M.B.A.


Dr. Sammy Farah has extensive vaccine expertise and almost 20 years of scientific, business and executive management experience in the biotechnology industry. He joined Turnstone Biologics from Synthetic Genomics Vaccines, Inc., where he served as President. Prior to that, he was Chief Business Officer of Immune Design Corp. And before then, Sammy was at Versant Ventures where he specialized in biotechnology investing and new company formation, and at Merck & Co., Inc. where he led technology support for multiple commercial vaccine franchises before joining the business development and licensing group to evaluate and execute new external technology and research partnerships. Dr. Farah earned an M.B.A. from the Wharton School at the University of Pennsylvania, a Ph.D. in biochemical engineering from Stanford University, and a B.S. in biochemical engineering from the Massachusetts Institute of Technology.

close
Patrick Machado

Patrick Machado


Patrick Machado is a co-founder of Medivation, Inc., a biopharmaceutical company, and has served on its Board of Directors since April 2014. Prior to his retirement in April 2014, Mr. Machado served as Medivation’s Chief Financial Officer since its inception in September 2003 and as its Chief Business Officer since December 2009. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately-held medical device company, as Vice President, Chief Financial Officer and General Counsel from 1998 to 2000, and as Senior Vice President and Chief Financial Officer from 2000 to 2001. From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation, to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University.

close
Robert Gould

Robert Gould


Robert Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at the Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. Throughout his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a B.A. from Spring Arbor College and a Ph.D. from the University of Iowa and completed postdoctoral studies at the Johns Hopkins University.

close
Stefan Larson, Ph.D.

Stefan Larson, Ph.D.


Dr. Larson joined Sectoral in 2018 as Partner – Private Equity, responsible for leading biotechnology private equity investments. Prior to joining Sectoral, Dr. Larson was an Entrepreneur-in-Residence and later Venture Partner with Versant Ventures, where he led the establishment of their Toronto-based Discovery Engine and was the founding CEO of Northern Biologics. Dr. Larson was also a co-founder of two medical device companies: Perimeter Medical Imaging, and Tornado Spectral Systems. He began his career at McKinsey & Company in San Francisco and Toronto. Dr. Larson received his B.Sc. in Biology from McGill University, and his M.Sc. in Molecular and Medical Genetics from the University of Toronto, prior to completing his Ph.D. in Biophysics at Stanford University.

close
Jeff Courtney

Jeff Courtney

In Memoriam

Jeff Courtney helped to form Turnstone Biologics and was an outstanding leader for FACIT (Fight Against Cancer Innovation Trust). Jeff’s life’s work and warm personality inspires all of us at Turnstone Biologics to drive forward our mission to help cancer patients, and we greatly miss his presence, leadership and friendship.

We are backed by top-tier investors who are committed to the company’s growth. We have raised approximately $50 million in venture capital financing since our inception.

Turnstone Biologics views strategic partnerships as a core component of our strategy and is interested in collaborating with biopharma companies, academic centers, and universities to transform patient care.

In December 2019, Turnstone Biologics announced a global collaboration and license agreement with Takeda to develop novel viral immunotherapies from Turnstone’s proprietary vaccinia virus platform targeting a broad range of cancer indications.

In the fall of 2017, Turnstone Biologics entered into a strategic research, option and license agreement with AbbVie for our Ad-MG1-MAGEA3 therapy and two research-stage candidates.

Careers

Turnstone Biologics’ team works with a sense of urgency to fulfill our mission. Our decision-making is driven by science and our therapeutics are designed with the patient in mind.

We value transparency, innovation, integrity and purpose as we collaborate to transform cancer care. If you’re a passionate person, and our mission and science excite you, Turnstone Biologics might be for you.

Team Member Openings

Turnstone Biologics is dedicated to excellence and innovation in every aspect of our science and business. We are actively looking for exceptional individuals who share our passion for developing and delivering next-generation viral immunotherapies. We offer competitive compensation and benefits and are an equal opportunity employer.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in being the key “go-to” animal tech person, then this role may be for you! The Animal Research Tech will bring hands-on experience with mouse husbandry and procedures such as syngeneic murine tumor models, intravenous and intramuscular injections, blood collection and necropsy, including experience with processing blood and tissues for ex vivo analysis. You will have experience working with some or all the following, as they relate to Animal Research Technical duties:

Primary responsibilities

Application of preclinical models to enable the translation of cancer therapies
Characterizing in vivo models, ex vivo assays, syngeneic tumor models, mouse models to optimize their application in preclinical and translational studies for targeted therapies, cancer immunotherapies and combination therapies
Be highly involved in mouse animal handling requiring subcutaneous, intraperitoneal and intravenous injections, frequent tumor measurements, and regular health monitoring of animals
Preforms blood collection through multiple routes, gaseous anaesthesia, tissue harvesting, and animal necropsies
Be involved in work with culture and/or cell separation methods; virus preparation; drug preparation
Additional responsibilities

Provide technical support for assays: viral titration, flow cytometry, and fluorescence microscopy
Operate lab equipment such as centrifuges, pH meters, analytical balances, spectrophotometers, light microscopes and other equipment as instructed
Performs simple or moderately complex technical procedures
Participates in data entry and data analysis, including application of statistical analysis techniques using standard software
May perform study-related administrative tasks. Compiles data from related and/or unrelated sources
Communicates findings to other lab members and maintains records of experimental data
Other duties as required

The details

This role is best suited for a some with the following:

in related science; Veterinary Technician Diploma; or an equivalent combination of education and experience.
2-5 years’ experience working in research in either an academic or biotech/pharma setting with strong mouse-handling skills
Working knowledge of CCAC guidelines, OMAFRA regulations and animal use protocols (AUPs)
Knowledge and familiarity with regulations, standards, and guidelines for care and use of vertebrate animals in teaching, research, and service
All work must be performed at the highest quality and with the highest regard for animal welfare.
Must have attention to detail and excellent record keeping skills
Must possess an excellent work ethic, maintain a professional attitude and maintain high standards to detail, being able to work independently and in a team environment with the ability to interact positively with other team members
Must be able to detect, analyze and resolve issues professionally as they arise
Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.
What’s in it for you?

In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. We also have opportunities for you to be a mentor to other team members. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

To Apply:

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

Located in Ottawa, the Research Associate will play key roles in the design, execution, and analysis of experiments to further the development of Turnstone Biologics’ growing pipeline. This is an exciting opportunity to work along side senior researchers and project teams to perform discovery and development research that will ultimately inform clinical development.

Our company’s technology is based around replicating oncolytic virus vaccines engineered to target tumors and launch massive tumor targeting immune responses. The core of this technology lies in the designing and building of these genetically constructed viruses.Your role will be to join a team of immunologists and molecular biologists who engineer and test these nanomedicines for preclinical and clinical development. There will be additional opportunities to work with our CMC team and other R&D members to continually refine the technology and manufacturing process for this class defining technology. If you have experience with manual, or robotic automation of, cell based and biochemical assays including ELISA, ELISpot assay, PCR and/or mammalian cell culture, are meticulous and driven to achieve; then this opportunity may be just what you are looking for.

The Research Associate will work along side senior researchers and project teams and participate in designing and executing cell-based immunology and virology assay following established laboratory standard operating procedures (SOPs). We have an open, transparent and dynamic culture that embraces scientific excellence, integrity, urgency, partnerships with key stakeholders and continuous learning/improvements.

The responsibilities include the following:

Participate in various aspects of in vitro and in vivo studies including but not limited to: organizing teams, scheduling and executing experiments, collecting, interpreting and communicating results
Prepare data/figures to present to senior research staff
Generate study reports in a timely manner
Contribute to a team-centric culture that embraces scientific excellence, integrity, and urgency

What’s in it for you?

In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. We also have opportunities for you to be a mentor to other team members. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

The Details

This role is best suited for someone with the following:

Must hold a MSc or Ph.D. in biology/immunology/oncology/pharmacology or a related field with 2+ years of experience or an acceptable combination of education and experience.
Robust understanding of innate and adaptive immune systems is required.
Experience with in vivo models, isolation and culture of primary cells (both mouse and human).
National Institutional Animal User Training Certification (NIAUT) an asset.
A working knowledge of immune based in vitro assays, flow cytometry and common molecular techniques.
Experience in T cell function/differentiation/signaling/regulation, phenotypic analysis of inhibitory and costimulatory targets and pathways and/or neoantigen biology and vaccines is highly preferred.

To Apply:

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

If you are interested in being a part of a growing Technical Operations team, then this role may be for you! As the Manager of Formulation and Drug Product Development, you will provide leadership, plan, direct, and coordinate all Drug Product development efforts to support our viral-based platforms. Reporting to the Director of Bioprocess Development & Manufacturing Sciences, you and your team will be responsible for:
• Manage DP development for entire portfolio of viral products
• Plan and direct lab experiments, with 1 reporting FTE by end of 2019
• Manage DP development at our external CRO partners
• Drive development of improved viral delivery systems (IV infusion, IT or IM injections) to enable optimization of pharmacy DP handling and administration
• Work closely with the Analytical Development team to ensure appropriate and robust assays are developed to enable stability testing of our DPs
• Lead all aspects of pre-formulation and formulation development across a range of DP images (liquid, and lyophilisation)
• Drive to definition of DP critical quality attributes through forced degradation studies and advanced analytical tools
• Travel required, 10%
• Participation in regulatory strategy and document authoring/reviewing for interactions with FDA, EMA, and Health Canada
• Present trended data, and recommendations in a cross functional Project Team

What’s in it for you?

In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. We also have opportunities for you to be a mentor to other team members. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

The Details

This role is best suited for someone with the following:
• 7+ years of overall experience within the biotech/pharmaceutical industry
• Scientist with advanced degree (MSc or PhD)
• Educated in one of the following fields: chemistry, biochemistry, virology, biotechnology
• Experience working with live virus formulations
• Experience designing, and planning accelerated studies to evaluate degradation pathways to define CQAs
• Strong interpersonal skills, and ability to manage several projects
• Leadership experience preferred

To Apply:

Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

The responsibilities for this position span across our multi-virus platform and include:

Our Manufacturing Operations (MFG) team is growing. As part of the Technical Operations organization, the MFG team is responsible for GMP manufacturing of Virus Banks, Drug Substance and Drug Product for our clinical-staged assets. MFG supports technology transfers and collaborates closely with the Process Development & Manufacturing Sciences team to develop and capture process knowledge and ensure overall manufacturing success. As an Associate Scientist/Engineer of Manufacturing Operations on the MFG team, you will report to the Associate Director, Manufacturing. You will be tasked with supporting manufacturing campaigns from end-to-end within our external contract manufacturing organization (CMO) network.

The responsibilities for this position span across our multi-modal platform and include:

– Support manufacturing campaigns with external CMO partners
– Support manufacturing batch readiness including process definition, raw material procurement, and batch documentation preparation
– Support ongoing batch monitoring including person-in-plant coverage
– Support cross functional teams troubleshooting and resolving issues with ongoing manufacturing runs
– Support manufacturing campaign closeout including the review of executed batch records and shipping/logistics of finished material
– Support process development, engineering runs, and other process scale-up related studies
– Support the identification and selection of new external CMO partners
– Support drafting of regulatory documentation including INDs, CTAs, etc.
– Represent the MFG team at Technical Operations cross-functional program meetings

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

    · This Associate Scientist role will be positioned in our Ottawa, Ontario or New York, NY office

    · Willingness to travel up to 10-30% to other Turnstone sites and/or external CMOs throughout North America (USA, Canada) and Europe

    · BSc in a science, engineering, or biotechnology related discipline; MSc considered an asset

    · 1-3 years’ experience in a technical operations or research/development role

    · Experience with live virus based therapeutic manufacturing such as viral immunotherapies, vaccines, cell and gene therapies, or other complex biologics

    · Experience with good manufacturing practices (GMP) in a clinical or commercial manufacturing setting

    · Experience with the qualification and operational use of single use, small scale mammalian cell culture, tangential flow filtration, and/or chromatography-based purification equipment and raw materials

    · Comfortable in a dynamic environment with competing priorities

    · Strong technical writing skills

    · Strong communication both written, and spoken

    · Strong interpersonal skills and a communication style that matches the Turnstone style: respectful, transparent, and constant

    · Excellent computer skills, including Microsoft Excel and PowerPoint

    To Apply:

    Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

The responsibilities for this position span across our multi-virus platform and include:

Our Manufacturing Operations (MFG) team is growing. As part of the Technical Operations organization, the MFG team is responsible for GMP manufacturing of Virus Banks, Drug Substance and Drug Product for our clinical-staged assets. MFG supports technology transfers and collaborates closely with the Process Development & Manufacturing Sciences team to develop and capture process knowledge and ensure overall manufacturing success. As a Senior Engineer (or Manager) of Manufacturing Operations on the MFG team, you will report to the Associate Director, Manufacturing. You will be tasked with leading manufacturing campaigns from end-to-end within our external contract manufacturing organization (CMO) network.

The responsibilities for this position span across our multi-modal platform and include:

– Lead manufacturing campaigns and serve as the primary interface with external CMO partners

– Lead manufacturing batch readiness including process definition, raw material procurement, and batch documentation preparation

– Lead ongoing batch monitoring including person-in-plant coverage

– Lead cross functional teams to troubleshoot and resolve issues with ongoing manufacturing runs

– Support manufacturing campaign closeout including the review of executed batch records and shipping/logistics of finished material

– Support process development, engineering runs, and other process scale-up related studies

– Support the identification and selection of new external CMO partners

– Support drafting of regulatory documentation including INDs, CTAs, etc.

– Represent the MFG team at Technical Operations cross-functional program meetings

– Serve as the primary interface with Bioprocess Development & Manufacturing Sciences, Quality Control, Quality Assurance, Supply Chain & Logistics, and/or Program Management on select projects, programs, and cross-functional workflows

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

    This Senior Engineer (or Manager) role will be positioned in our Ottawa, Ontario or New York, NY office

    · Willingness to travel up to 30-50% to other Turnstone sites and/or external CMOs throughout North America (USA, Canada) and Europe

    · BSc in Chemical Engineering or in other related engineering discipline (biochemical, biological, biomedical, mechanical); MSc in a related scientific discipline also considered

    · 5-7 years’ experience in a manufacturing operation, manufacturing sciences and technology, manufacturing technical support, or quality engineering role

    · Experience with live virus based therapeutic manufacturing such as viral immunotherapies, vaccines, cell and gene therapies, or other complex biologics is considered important

    · Experience with aseptic manufacturing processes such as the fill/finish of drug product and/or non-terminally sterilized drug substance is considered important

    · Experience with good manufacturing practices (GMP) in an early clinical to late phase clinical manufacturing setting is considered important

    · Experience managing external relationships such as CMO partners or clients as a CMO provider considered an asset

    · Experience with the qualification and operational use of single use, small scale mammalian cell culture, tangential flow filtration, and/or chromatography-based purification equipment and raw materials

    · Comfortable leading a cross-functional team in time sensitive, high pressure, and high-risk situations (e.g. manufacturing issue resolution) considered important

    · Experience leading a team of direct reports is considered an asset

    · Comfortable in a dynamic environment with competing priorities

    · Strong technical writing skills

    · Strong communication both written, and spoken

    · Strong interpersonal skills and a communication style that matches the Turnstone style: respectful, transparent, and constant

    · Excellent computer skills, including Microsoft Excel and PowerPoint

    To Apply:

    Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

The responsibilities for this position span across our multi-virus platform and include:

Translate Clinical Development Plan requirements into an actionable end-to-end supply plan, evaluating multiple different scenarios at a time
Serve as the primary interface with Clinical Operations, Quality, Regulatory Affairs, Manufacturing Operations and Process Development/Manufacturing Sciences to ensure coordination of all activities necessary to develop the forecast and ensure an adequate supply plan
Lead internal cross-functional team on execution of project timelines and coordinate labeling, packaging, and shipment of packed supplies with external suppliers
Manage and maintain IMP distribution and return drug plans and manage any documentation associated, in compliance with GMP and industry standards
Monitor inventory levels as well as expiry and re-supply needs; communicate needs and de-risk as appropriate across the entire supply chain (bulk drug substance through IMP supplies)
Promptly identify and escalate risks to study timelines or clinical supplies, from a supply chain perspective, to all key stakeholders
Support implementation of and utilize systems to effectively manage key product/project activities
Articulate clinical supply chain management processes and strategies to key stakeholders
Review and update existing procedures and SOPs; identify the need for and assist in the establishment of new procedures and SOPs

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

The responsibilities for this position span across our multi-virus platform and include:

Lead group of technologists to support testing samples from our bioprocess development, reasearch, product development, and analytical development teams (Includes scheduling, training, qualifying, etc.)
– Manage testing priority and schedule to meet client timelines and overall company goals
– Establish and oversee procedures, SOPs, templates, work flows to support all lab work and method tech transfer to external vendors
– Execute and oversee tech transfers to non-GMP vendors
– Work very closely with the analytical development (AD) team to track and trend methods that are used in the lab
– Stay up to date on new instrumentation and methods to support testing (with AD)
– Embody an attitude of continuous improvement, with a focus on operational excellence. Operational excellence will be focused on determining, measuring, and reporting key performance indicators – we can’t fix or improve anything that we can’t measure and quantify.

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

    his role is best suited for a scientist with the following:
    – 5+ years working in biotech or pharmaceutical company with at least 3 years managing a Lab team of 2 or more direct reports
    – Education: Advanced degree (MS) in biochemistry, molecular biology, or relevant field preferred
    – Experience with analytical tech transfer to external contract testing organization or other external entity
    – Savvy with spreadsheeting, biostatistics, and advanced data treatment platforms (e.g., JMP)
    -Agile and comfortable using IT platforms to support organizing and reporting results/samples/tasks
    – Experience with assay qualification and what makes a robust assay
    – Excellent communication and proficient at extracting needs from clients, with a focus at building partnerships across a wide range of customers, under aggressive timelines and expectations.
    – Experience managing competing priorities from multiple clients, and a master at facilitating prioritization across a wide range of customers.

    To Apply:

    Please click here to apply!

    Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing team that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com.

The responsibilities include the following:

Drive the development of the company’s Quality strategy and policies.
Oversee company-wide documentation practices, record keeping, training, auditing, raw material qualification and

What’s in it for you?

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Thursday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

Responsibilities include: working in a Turnstone lab, running complex analytics to support product characterization, preclinical study sample testing, and analytical development.

Experience & Qualifications:

    This role is best suited for an analyst with the following:
    – 2+ years of hands-on experience in the lab (school lab experience counts) performing several methods such as:
    • virological and cellular assays (tissue culture, plaque assay, killing assay, TCID50, infections, etc)
    • molecular assays (qPCR, PCR, Bradford, ELISAs, Western blot, etc)
    -Education: diploma or degree in biochemistry, biotechnology, or relevant field
    – Agile in a lab setting, able to learn new methods
    – Experience following a procedure several times to generate precise and accurate results
    – Careful and diligent method execution and reporting
    – Organized and able to manage time to enable the execution of several experiments at once when required
    – Very comfortable using Microsoft applications (Excel, Word, PowerPoint). Experience with analytical software such as JMP would be an asset.

    To Apply:
    Please click here to apply!

    Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics Inc. is the leading virus-based immunoncology biotechnology company developing novel oncolytic vaccine therapeutics for cancer patients. Our first-in-class platform technology attacks tumours using a two-pronged approach: targeted and robust tumour killing using an oncolytic virus, in combination with a cancer vaccine that generates long-lasting anti-tumour immune responses. Turnstone is building a world-class, high-performing team that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Canada and New York, USA. For more information, please visit www.turnstonebio.com.

Position Overview:

Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another Thursday at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

Responsibilities
• Partner with internal and external stakeholders to track orders, prepare documentation and coordinate/monitor the delivery of shipments, globally. Ensure full compliance of import/export operation activities are met based on applicable regulatory requirements.
• Effectively and proactively manage inquiries and any logistics-related issues received from internal and external customers, carrier companies, Customs or other regulatory bodies.
• Monitor expiration of permits and import licenses, and prepare documentation for new applications or renewals, as required.
• Logistics and inventory coordination/traceability – ensure accuracy of transactions to maintain reliable inventory reports.

What’s in it for you?

In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. We also have opportunities for you to be a mentor to other team members. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

    Requirements:
    • BS/BA required (science or business preferred), or equivalent combination of education and experience.
    • Requires a minimum of 3-5 years’ experience that includes in-depth understanding of cGMP Logistics operations in the Pharma/Biotech field or relevant field.
    • Must have a working knowledge of Trade Compliance responsibilities, on both the import and export sides of the logistics business.
    • Cold Chain experience required.
    • Working experience and knowledge of applicable regulatory requirements (FDA, CDC, USDA, EU, FAA, IATA, DOT, Customs, and OSHA).
    • Experience / ability to understand and develop procedures and other controlled documents required.

    To Apply:

    Please click here to apply!

    Turnstone Biologics welcomes and encourages applications from people with disabilities. Accommodations are available on request for candidates taking part in all aspects of the selection process. We thank all applicants for their interest, however, only those selected will be invited for an interview.

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

We are currently seeking a highly qualified, motivated and experienced individual for the position of Senior Accountant. This position will interact with various levels of management and third-party vendors. The ideal candidate is a licensed CPA with biotechnology or pharmaceutical experience.
This position will have accountability and responsibility for supporting aspects of the company’s financial reporting requirements including the preparation of monthly and quarterly close packages to ensure accuracy and quality of financial statements and disclosures in accordance with US GAAP, journal entry and account reconciliations, variance analytics and ability to assist in addressing technical accounting issues arising from business transactions. This candidate will primarily be responsible for meeting each month-end close and all supporting documentation for proper accruals.
This role will provide analytical and strategic support to Clinical Operations, Regulatory, Technical Operations and other R&D business owners. This role requires critical thinking skills, effective organizational skills, excellent written and verbal communication skills, and a strong ability to build effective relationships across the Company.

RESPONSIBILITIES
• Assist in gathering data from key stakeholders to prepare schedules and analytics
• Responsible for supporting aspects of month end close such as accruals, journal entries, account reconciliations, technical accounting and purchase to pay and payroll cycle
• Work with external auditor to support the audit process
• Support the timely and accurate preparation, review and completion of all month and quarter end close package’s
• Ownership of monthly & quarterly accruals
• Comply with internal controls and processes over financial reporting
• Staying abreast of new accounting principles, SEC reporting and general trends within the financial services industry
• Assess quarterly transactions for disclosure, and assist with technical accounting and IRS ruling research, draft memos
• Ensures integrity of the company’s accounting system, including new account, department and project set-up, financial report development and maintenance, and interfaces between payroll, equity, financial planning and expense management systems to the general ledger
• Provides support to all other teams across the company as needs arise, including special projects, system improvements or ad-hoc financial analyses as assigned

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell vaccine to harness an individual’s own immune system to attack the tumor, preventing recurrence and delivering a cure. Turnstone’s robust pipeline of early-stage compounds, based on its MG1 oncolytic virus platform, are in development for multiple solid tumors and are being evaluated in combination with other cancer immunotherapies, including checkpoint inhibitors, to drive unprecedented, durable T-cell immune responses and strong anti-tumor activity and prevent recurrence. Turnstone is building a world-class, high-performing company that embraces being a learning organization with a sense of urgency. Turnstone has a seasoned board of directors and venture capital partners, is enrolling clinical studies, has a rich development portfolio, and highly active R&D efforts led by a world-class scientific management team. Turnstone is co-located in Ottawa, Hamilton, Canada and New York, USA.

Position Overview:
Imagine coming to work every day where over-communication, transparency, teaching, listening, asking, thinking, working hard, and having fun are normal – actually, expected? Imagine having a coach, mentor, peers, and partners where candid feedback, self-improvement, risk taking, failing, learning from that failing, and succeeding are what we call ‘another day at Turnstone’? At Turnstone, the science drives decision making, and our drugs are designed with the patient in mind. Like the disease we’re fighting, our platform is complex, and transformative. If you’re a passionate person, and our science excites you – this opportunity may be for you.

We are currently seeking a highly qualified, motivated and experienced individual for the position of Accounting Manager. This position will interact with various levels of management and third-party vendors. The ideal candidate is a licensed CPA with biotechnology or pharmaceutical experience.
This position will have accountability and responsibility for supporting aspects of the company’s financial reporting requirements including the preparation of monthly and quarterly close packages to ensure accuracy and quality of financial statements and disclosures in accordance with US GAAP, journal entry and account reconciliations, variance analytics and ability to assist in addressing technical accounting issues arising from business transactions. This candidate will primarily be responsible for meeting each month-end close and all supporting documentation for proper accruals.
This role will provide analytical and strategic support to Clinical Operations, Regulatory, Technical Operations and other R&D business owners. This role requires critical thinking skills, effective organizational skills, excellent written and verbal communication skills, and a strong ability to build effective relationships across the Company.

RESPONSIBILITIES
• Assist in gathering data from key stakeholders to prepare schedules and analytics
• Responsible for supporting aspects of month end close such as accruals, journal entries, account reconciliations, technical accounting and purchase to pay and payroll cycle
• Work with external auditor to support the audit process
• Support the timely and accurate preparation, review and completion of all month and quarter end close package’s
• Ownership of monthly & quarterly accruals
• Comply with internal controls and processes over financial reporting
• Staying abreast of new accounting principles, SEC reporting and general trends within the financial services industry
• Assess quarterly transactions for disclosure, and assist with technical accounting and IRS ruling research, draft memos
• Ensures integrity of the company’s accounting system, including new account, department and project set-up, financial report development and maintenance, and interfaces between payroll, equity, financial planning and expense management systems to the general ledger
• Provides support to all other teams across the company as needs arise, including special projects, system improvements or ad-hoc financial analyses as assigned

What’s in it for you?
In this role, you will have the opportunity to develop your ability to think both strategically and drive fast-paced execution. With our company size and growth we will give you plenty of opportunities for you to be an inspirational and collaborative co-functional leader. Passionate about being a part of a critical function of a growing company and continuous learning? We will have plenty of that for you!

We are in the early stages of building strategies, structures and process so this role will be busy and expanding. You would have the opportunity to create something new and ‘WOW!’ all of us and grow right along with the company.

Experience & Qualifications:

Notice to Recruiters: Turnstone Biologics values our recruiting partnerships, but to protect the interest of all parties, we do not accept unsolicited resumes from recruiters. All recruiting is managed through our human resources department.

Contact

Ottawa

12 York Street, 3rd Floor,
Ottawa, ON K1N 5S6, CA
(613) 421-8930

New York City

920 Broadway, 16th Floor,
New York, NY 10010, US
(613) 421-8930

General

Please contact us with any questions
or comments.

Info@turnstonebio.com

Media

Please contact Canale Communications
for any media inquiries.

Heidi@canalecomm.com